<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01353339</url>
  </required_header>
  <id_info>
    <org_study_id>CIHR MOP 222493, 2010-292</org_study_id>
    <nct_id>NCT01353339</nct_id>
  </id_info>
  <brief_title>Quinolone Prophylaxis for the Prevention of BK Virus Infection in Kidney Transplantation: A Pilot Study</brief_title>
  <official_title>Quinolone Prophylaxis for the Prevention of BK Virus Infection in Kidney Transplantation: A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ottawa Hospital Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Canadian Institutes of Health Research (CIHR)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>St. Paul's Hospital, Canada</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Vancouver General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Alberta</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Manitoba</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Health Network, Toronto</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>St. Michael's Hospital, Toronto</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>St. Joseph's Healthcare Hamilton</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>London Health Sciences Centre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>McGill University Health Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dalhousie University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ottawa Hospital Research Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Research Questions:

      Efficacy, safety and feasibility of a 3-month course of levofloxacin in a pilot study will be
      assessed.

        1. Under efficacy, this pilot will determine whether levofloxacin can decrease the
           incidence of BK viruria and peak urine BK viral load.

        2. Under safety, this pilot will determine the incidence of adverse events with
           levofloxacin.

        3. Under feasibility, this pilot will determine the number of kidney transplant patients
           randomized over an eight month enrolment period, adherence to the levofloxacin and
           frequency of patient drop-out and loss to follow-up
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      BK virus infection has emerged as a major complication in renal transplantation leading to a
      significant reduction in graft survival. There are currently no proven strategies to prevent
      or treat BK virus infection. Quinolone antibiotics, such as levofloxacin, have demonstrated
      activity against BK virus. The investigators hypothesize that administration of a quinolone
      antibiotic, when given early post-transplantation, will prevent the establishment of BK viral
      replication in the urine and thus prevent systemic BK virus infection. A non-randomized study
      in kidney transplant recipients found that patients given levofloxacin or ciprofloxacin had a
      significantly lower incidence of BK viremia compared to those not receiving a quinolone (4%
      versus 24.5%, P=0.02).

      Objective: The primary objective of the full trial will be to determine if the quinolone
      levofloxacin decreases the occurrence of doubling creatinine, transplant failure or death in
      kidney transplant recipients. The aim of this pilot trial is to assess the efficacy, safety
      and feasibility of a 3-month course of levofloxacin in the kidney transplant population.

      Results from this pilot study will provide vital information to design and conduct a large,
      multi-centre trial to determine if quinolone therapy decreases meaningful clinical outcomes
      in kidney transplantation. If levofloxacin significantly reduces BK viruria and urine viral
      loads in kidney transplantation it will provide important justification of biologic effect to
      progress to the larger trial. If the full trial shows that levofloxacin significantly reduces
      BK infection and improves outcomes, its use in renal transplantation will be strongly
      endorsed given the lack of proven therapies for this condition.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2011</start_date>
  <completion_date type="Actual">October 2014</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy: The time to occurence of BK viruria</measure>
    <time_frame>12 months post-transplantation</time_frame>
    <description>BK viruria will be defined as ≥1000 copies/mL ok BK virus DNA in the urine.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>12 months</time_frame>
    <description>Incidence and type of all adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute rejection</measure>
    <time_frame>12 months</time_frame>
    <description>Incidence of Acute rejection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clostridium difficile associated diarrhea</measure>
    <time_frame>12 months</time_frame>
    <description>Incidence of microbiologically confirmed clostridium difficile associated diarrhea</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infections</measure>
    <time_frame>12 months</time_frame>
    <description>Incidence of other infections (viral, bacterial and fungal) based on established guidelines</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quinolone resistance</measure>
    <time_frame>12 months</time_frame>
    <description>Incidence of quinolone resistance where a quinolone would have been a therapeutic option</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of levofloxacin on immunosuppressive drug doses and blood levels</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transplant failure</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients transplanted</measure>
    <time_frame>12 months</time_frame>
    <description>Number of patients transplanted during the 8 month recruitment period who are randomized into the trial</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adherence</measure>
    <time_frame>12 months</time_frame>
    <description>Proportion of randomized participants who are adherent to the protocol.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of quinolones</measure>
    <time_frame>12 months</time_frame>
    <description>Use of quinolones outside of the protocol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patient drop-out and loss to follow-up</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantitative BK urine viral load</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BK viremia</measure>
    <time_frame>12 months</time_frame>
    <description>Time to occurence of BK viremia, defined as ≥250 copies/mL of BK virus DNA in the plasma</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">154</enrollment>
  <condition>Disease Due to BK Polyomavirus</condition>
  <condition>Kidney Transplant Infection</condition>
  <arm_group>
    <arm_group_label>sugar pill</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>levofloxacin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levofloxacin</intervention_name>
    <description>500mg, PO, once daily for 3 months</description>
    <arm_group_label>sugar pill</arm_group_label>
    <arm_group_label>levofloxacin</arm_group_label>
    <other_name>Apo-levofloxacin</other_name>
    <other_name>DIN 02284707</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  a primary or repeat kidney transplant recipient (deceased or living donor)

          -  age greater or equal to 18 years

        Exclusion Criteria:

          -  Unable to provide informed consent

          -  Greater than 5 days post-transplantation

          -  BK virus nephropathy with a previous transplant

          -  History of allergic reaction to any quinolone antibiotic

          -  History of quinolone associated tendonitis or tendon rupture

          -  Corrected QT interval prolongation on EKG as defined by Al-Khatib

          -  Concomitant use of medication known to prolong the QT interval such as class IA
             antiarrhythmic drugs (e.g. quinidine, procainamide, disopyramide), class III
             antiarrhythmic drugs (e.g. amiodarone, sotalol), azole antifungals (e.g. fluconazole)
             or macrolide antibiotics (e.g. erythromycin)

          -  Pregnant or breastfeeding as safety of levofloxacin not established

          -  Requires quinolone antibiotic for more than 14 days (e.g. for UTI prophylaxis)

          -  Recipient of a multi-organ transplant (e.g. kidney-pancreas)

          -  Currently enrolled in another interventional trial

          -  Previously enrolled in this study

          -  History of rhabdomyolysis

          -  Significant allergic reaction to ≥ 3 classes of antibiotics as these patients may have
             no other option other than quinolones for routine infection.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Greg Knoll, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ottawa Hospital Research Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Capital Health - University of Alberta Hospital</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2B7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vancouver General Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 1M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Paul's Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6Z 1Y6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Winnipeg Health Science Center</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>QEII Health Science Center</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Joseph's Healthcare</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 4A6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>London Health Science Center</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5A5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ottawa Hospital</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Health Network</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2N2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Michael's Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McGill University Health Center</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3A 1A1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>October 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 11, 2011</study_first_submitted>
  <study_first_submitted_qc>May 12, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 13, 2011</study_first_posted>
  <last_update_submitted>October 14, 2014</last_update_submitted>
  <last_update_submitted_qc>October 14, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 15, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Kidney Transplant</keyword>
  <keyword>BK Polyomavirus Infection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Levofloxacin</mesh_term>
    <mesh_term>Ofloxacin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

